Community, Diagnose and Manufacturing

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Community

Diagnose

Manufacturing

Urinary Incontinence Revisited: George Kuchel & Alison Huang

GeriPal

JUNE 20, 2024

It’s under recognized, under diagnosed, under treated, under discussed, understudied as a result. But that combination is actually quite common, and it’s quite challenging to diagnose and manage, at least in the traditional sense. Clinicians don’t ask about it. George 19:37 Exactly, exactly. Alison 29:08 Yes.

IT Patient-Centered Patients Clinic

Direct-to-consumer advertising distorts prescription drugs’ benefits and costs

Common Sense Family Doctor

FEBRUARY 15, 2025

On Sensible Medicine, Dr. Edward Livingston pointed out that the manufacturer, AbbVie, spent $580 million on DTCA for this drug in 2023, or $290 for each of the 2 million potential patients in the United States. The annual price of risankizumab is $288,000, so this is still a huge bargain for the company given the potential returns.

Family Physician

Family Physician Manufacturing Families Family

Primary Care Digest

Urinary Incontinence Revisited: George Kuchel & Alison Huang

Direct-to-consumer advertising distorts prescription drugs’ benefits and costs

Stay Connected